HSMD

Meet HSMD Research, a game-changing free somatic tool for academics

Thu, 22 May 2025 14:32:15 GMT

Welcome to HSMD Research, a free source of critical somatic data on the top 25 clinically significant genes. Designed for academic researchers, this knowledge base offers expert-curated insights into gene annotations, variant distribution, functional impact, clinical relevance and drug associations, proving a strong foundation for hypothesis generation and discovery.

With data from over 870,000 real-world clinical oncology cases and knowledge curated by highly experienced variant experts, HSMD Research can help you specify genes and variants of interest and identify the best-fit cell lines and disease models for your research.

In this webinar, discover HSMD Research’s capabilities with Dr. Umadevi Thirumurthi and learn more about its:

Role in cancer research
Interactive features
Practical applications, including the study of tumor suppressors, oncogenes, targeted therapy responses, DNA repair mechanisms, etc.

How clinical labs can confidently assess cancer-associated variants with...

Thu, 07 Dec 2023 14:18:44 GMT

Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations is critical. The advent of next-generation sequencing (NGS) has led to an exponential increase in the number of variants detected in tumor testing, posing a challenge for clinical cancer genetics professionals seeking to confidently discern clinically relevant mutations that can guide patient care decisions.

Join Dr. Umadevi Thirumurthi, Associate Director of Global Product Management for Oncology at QIAGEN Digital Insights as she discusses how the Human Somatic Mutation Database (HSMD), an expert-curated somatic variant database, can enhance your clinical NGS workflow.

Indication Expansion and Repurposing of PIK3CA Kinase Inhibitors: Systems...

Wed, 20 Sep 2023 07:38:56 GMT

Here we demo tools to rapidly guide drug repurposing and indication expansion, using alpelisib—a PI3Kα inhibitor approved for metastatic breast cancer—as a case study. The speaker shows how activating mutations in the PIK3CA gene, a key oncogene, not only prevalent in breast cancer but also significantly present in oral cancers, an area with few active clinical trials and limited therapeutic development. By merging real-world mutation data, clinical outcomes, and pathway-based network modeling, the analysis shows that PIK3CA mutations in oral cancer correlate with poorer survival, and that inhibiting PIK3CA activity could reduce disease progression. Further, the session used public dataset comparisons to identify non-oncologic diseases (e.g., lupus, heart disease) that share similar biology, suggesting future repurposing potential. It concluded by identifying possible combination therapy partners through anti-matching expression patterns, showcasing a full workflow from hypothesis generation to target validation in under an hour.

How to simplify somatic NGS analysis & reduce literature review time by 90%...

Wed, 29 Mar 2023 15:29:52 GMT

Across clinical oncology applications, from molecular testing to cancer research, the ability to identify potentially actionable genomic and genetic alterations to exploit the molecular vulnerabilities of cancer is a burgeoning field. Due to the sporadic nature of somatic cancers and the expansion of next-generation sequencing, the number of variants detected through tumor testing is growing exponentially, presenting a challenge to clinical cancer genetics professionals working to confidently identify meaningful mutations that could influence decision-making at point-of-care.

Join Chelsea Alexander, a certified genetic counselor, and Aarthi Goverdhan, our lead oncology application development scientist, for this live webinar to discover a new database that can streamline your somatic NGS analysis and significantly reduce your literature review time—by up to 90%!

In this webinar, we will introduce you to the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. Available as a web-based application, this expert-curated resource contains data from over 419,000 real-world clinical oncology cases combined with insights from the QIAGEN Knowledge Base, providing clinically observed variant frequencies across diseases, and diving deep into gene-level, alteration-level and disease-level information. Users can easily search and explore mutational characteristics across genes, synthesize key findings from drug labels and professional guidelines, explore clinical trials, and receive detailed annotations for each observed variant. In addition, users can interrogate a bibliography of over 170,000 PubMed articles and access detailed alteration-specific summaries written by PhD scientists.

Accelerate R&D in New Cancer Drug Development: A Translational Research...

Tue, 10 Jan 2023 17:23:29 GMT

The paradigm of predictive biomarkers of therapeutic responses to drug intervention has dramatically transformed cancer drug development. However, as translational research on cancer drug development rapidly evolves, the ability to confidently and efficiently identify specific oncogenes and tumor suppressors involved in oncogenesis is becoming increasingly difficult.

This webinar will focus on the translational research applications of the Human Somatic Mutation Database (HSMD)—a somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. Available as a web-based application, this expert-curated resource contains content from over 410,000 real-world clinical oncology cases combined with content from the QIAGEN Knowledge Base, providing gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across diseases. Users can easily search and explore mutational characteristics across genes, synthesize key findings from drug labels, clinical trials, and professional guidelines, and receive detailed annotations for each observed variant. In addition, users can interrogate a bibliography of over 170,000 variant-specific PubMed articles and access individual summaries of alteration-type specific information written by Ph.D. scientists.

Viewers will:

Learn what content sources power HSMD
Understand how to use and apply HSMD for multiple applications, including translational research and pharmaceutical development
Examine a use case of how to use HSMD to accelerate research and development in new cancer drug development programs
Receive a complimentary 5-day trial of HSMD.

Expanding Germline and Somatic Variant Knowledge and Interpretation

Thu, 08 Sep 2022 19:37:27 GMT

In this 60-minute webinar, learn how the online resources of the Human Gene Mutation Database (HGMD) Professional and the Human Somatic Mutation Database (HSMD) can improve the quality, and decrease the time needed for variant classification and interpretation.

Users will discover how to use both these expert-curated resources for the annotation and understanding of next-generation sequencing data in routine clinical and translational research.

Somatic variants investigation in critical regulatory pathways

Thu, 25 Aug 2022 15:10:11 GMT

This training will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and Human Somatic Mutation Database (HSMD) to identify key somatic variants associated with regulatory genes in ‘omic data and study the genomic characteristics of both target and disease to better understand the clinical relevance. Identifying and studying the genomic characteristics of drug targets and important genes are of great interest to many researchers as it can offer new insights into improving drug discovery and precision medicine. In this 90-minute training, the Human Somatic Mutation Database (HSMD) will be introduced for genomic investigation. HSMD is a web-based database containing data for hundreds of thousands of variants within the context of solid tumors and hematological malignancies. Specifically, HSMD provides gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across cancer types.

Attendees will learn how to:

· Use IPA to identify key regulators within a dataset of interest

· Use HSMD to investigate variants for target genes and cancer type of interest

· Synthesize key findings from drug labels, clinical trials, and PubMed articles for specific alterations and cancer types

Click here to learn more about HSMD and IPA.

Target discovery through QIAGEN IPA and HSMD

Fri, 13 May 2022 15:18:03 GMT

Identifying and studying the genomic characteristics of drug targets and important genes are of great interest to many researchers as it can offer new insights into improving drug discovery and precision medicine. In this 90-minute training, QIAGEN Human Somatic Mutation Database (HSMD) will be introduced for genomic investigation. HSMD is a web-based database containing data for hundreds of thousands of variants within the context of solid tumors and hematological malignancies. Specifically, HSMD provides gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across diseases. Accordingly, this webinar will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and HSMD to identify key regulators in ‘omic data and study the genomic characteristics and landscape of both target and disease.

Attendees will learn how to:
• Use IPA to identify key regulators within a dataset of interest
• Use HSMD to investigate variants for target genes and diseases of interest
• Synthesize key findings from drug labels, clinical trials, and PubMed articles for specific alterations and diseases

Access to real-world data and 2 decades of expert curation

Wed, 20 Apr 2022 07:43:42 GMT

Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular vulnerabilities of cancer is becoming increasingly difficult. Due to the sporadic nature of somatic cancers, the number of detected variants is exponentially growing, challenging scientists to confidently identify meaningful mutations that could influence or improve decisions in experimental design, at point-of-care, or in drug development.

In this webinar, we will introduce you to the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. Available as a web-based application, this expert-curated resource contains content from over 300,000 real-world clinical oncology cases combined with content from the QIAGEN Knowledge Base, providing gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across diseases. Users can easily search and explore mutational characteristics across genes, synthesize key findings from drug labels, clinical trials, and professional guidelines, and receive detailed annotations for each observed variant. In addition, users can interrogate a bibliography of over 150,000 variant specific PubMed articles and access individual summaries alteration-type specific information written by PhD scientists.

In this webinar, you will learn:

What content sources power HSMD
How to use and apply HSMD for multiple applications, including research, molecular testing, and pharmaceutical development
When and where you can access HSMD

Identify meaningful mutations in somatic tumor testing

Mon, 14 Feb 2022 14:54:55 GMT

From Information Overload to Actionable Insights

Precision medicine is transforming cancer care, with next-generation sequencing (NGS) enabling the simultaneous analysis of multiple genomic alterations with therapeutic implications. However, due to the sporadic nature of somatic cancers and the increasing uptake of NGS testing, the number of detected variants is exponentially growing, challenging labs to confidently identify meaningful mutations that could influence or improve decisions at the point of care. Approximately 50 percent of the oncologists in the United States find NGS results sometimes or often difficult to interpret, while 31 percent of small to medium-sized labs in Europe view a lack of knowledge and exposure to routine analyses and interpretation as the most critical bottleneck in NGS testing [1-2].

In this webinar, Ana Krivokuca will present a real-world use case of how the Institute for Oncology and Radiology of Serbia (IORS), a national cancer research center that provides routine NGS testing for cancer patients, uses the Human Somatic Mutation Database (HSMD) in their NGS testing pipeline to validate, assess, and better understand the clinical significance of detected variants.

A new somatic database from QIAGEN, HSMD combines two decades of expert-curated content with data from over 300,000 real-world clinical oncology cases to provide deep genomic insight into the molecular characterizations of a patient’s tumor. Easy to search with new content added weekly, HSMD enables users to explore key genes or mutations with driving properties or clinical relevance, search for associated treatment options, evaluate secondary findings, and develop customized gene panels.

Attendees will:

Learn how IORS uses HSMD to identify actionable variants, analyze complex reports, evaluate secondary findings, and design custom gene panels.
Explore HSMD content and features through a virtual demonstration.
Receive a complimentary, five-day trial of HSMD.

Speaker:
Ana Krivokuca, PhD
Head of Department for Genetic Counseling
Institute for Oncology and Radiology of Serbia